CVS Health (NYSE:CVS) Upgraded to “Overweight” at Cantor Fitzgerald

CVS Health (NYSE:CVS) was upgraded by equities researchers at Cantor Fitzgerald from a “neutral” rating to an “overweight” rating in a research note issued to investors on Wednesday,Briefing.com Automated Import reports.

A number of other brokerages have also recently weighed in on CVS. Edward Jones raised shares of CVS Health from a “hold” rating to a “buy” rating in a research report on Thursday, January 30th. Mizuho reduced their target price on shares of CVS Health from $73.00 to $66.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Leerink Partners increased their price target on CVS Health from $51.00 to $55.00 and gave the company a “market perform” rating in a report on Tuesday. Barclays decreased their target price on CVS Health from $75.00 to $71.00 and set an “overweight” rating for the company in a research report on Thursday, November 7th. Finally, Deutsche Bank Aktiengesellschaft raised shares of CVS Health from a “hold” rating to a “buy” rating and set a $66.00 price target for the company in a report on Tuesday, December 3rd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $67.78.

CVS Health Trading Up 15.8 %

Shares of CVS traded up $8.69 during mid-day trading on Wednesday, hitting $63.69. The company had a trading volume of 27,272,732 shares, compared to its average volume of 12,906,413. The company has a quick ratio of 0.59, a current ratio of 0.80 and a debt-to-equity ratio of 0.80. The stock has a market cap of $80.14 billion, a PE ratio of 16.22, a P/E/G ratio of 0.60 and a beta of 0.61. CVS Health has a 1-year low of $43.56 and a 1-year high of $80.75. The business’s 50-day simple moving average is $50.61 and its 200-day simple moving average is $55.92.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 10.72% and a net margin of 1.36%. Sell-side analysts forecast that CVS Health will post 5.14 earnings per share for the current year.

Institutional Trading of CVS Health

Several hedge funds have recently added to or reduced their stakes in CVS. Clearbridge Investments LLC boosted its holdings in shares of CVS Health by 74.1% in the fourth quarter. Clearbridge Investments LLC now owns 4,397,121 shares of the pharmacy operator’s stock valued at $197,387,000 after acquiring an additional 1,872,144 shares in the last quarter. Brandywine Global Investment Management LLC lifted its position in CVS Health by 29.6% in the fourth quarter. Brandywine Global Investment Management LLC now owns 2,848,986 shares of the pharmacy operator’s stock worth $127,891,000 after purchasing an additional 650,832 shares during the period. Allianz SE bought a new position in CVS Health during the 4th quarter valued at $3,648,000. Allstate Corp bought a new stake in shares of CVS Health in the 4th quarter worth $1,680,000. Finally, DnB Asset Management AS lifted its holdings in shares of CVS Health by 5.5% in the fourth quarter. DnB Asset Management AS now owns 219,374 shares of the pharmacy operator’s stock valued at $9,848,000 after buying an additional 11,483 shares during the period. Institutional investors own 80.66% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.